Contract

Temp Director

Clinical Development

Posted on 9/12/2025

Revolution Medicines

Revolution Medicines

1,001-5,000 employees

Clinical-stage oncology company developing RAS inhibitors

No salary listed

San Carlos, CA, USA

Hybrid

Hybrid work arrangement indicated by #LI-Hybrid.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • Bachelor’s Degree (life sciences preferred) plus Advanced Clinical/Science Degree is required (e.g., PharmD, PhD, MSN, MPH, etc.).
  • Minimum 10+ years experience in clinical development required (Pharma R&D experience outside of a clinical development role also considered pending transferability of skills and responsibilities).
  • Extensive experience working with the principles and techniques of data analysis, interpretation, and clinical relevance as related to the pharmaceutical/biotech industry.
  • Experience in independent generation of trial design, protocol writing/ICF (writing or amendment), constructing appropriate CRF and coordinating cross-functionally.
  • In-depth therapeutic area experience/expertise, and relevant clinical trial experience (or clear ability to adapt with transferable skills).
  • Strong knowledge of medical aspects of GCP (Good Clinical Practice), ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), FDA, EMA and other relevant guidelines and regulations is required.
  • Proven ability to work effectively and efficiently within cross-functional teams involved in the drug development process; proven ability to efficiently integrate multiple perspectives into the CDP.
  • Experience authoring regulatory briefing packs, write responses to Health Authority questions, and proven ability to contribute to strategic approach and cross-functional coordination in support of regulatory activities/interactions.
  • Demonstrated success in driving various aspects of cross-functional study level strategy, e.g. study design, supporting feasibility and timelines/budget projections, protocol amendment requirements. Ability to drive relevant discussion at key internal decision-making bodies/governance.
  • Proven ability to build and maintain strong relationships and contribute to interactions with external key opinion leaders to optimize clinical programs (e.g. advisory boards, individual engagements, steering committees, etc.).
  • Experience in (or clear ability) investigator engagement to optimize clinical trial conduct. Includes presenting at investigator meetings.
  • Strong orientation to teamwork. Excellent leadership, communication, and interpersonal skills with the ability to inspire, motivate and mentor across a diverse team.
  • Experience in mentoring other clinical scientists. Experience or clear potential as an effective line manager.
  • Expertise in building and maintaining strong relationships with internal and external stakeholders.
  • Superb strategic thinking and analytical skills, with the ability to make data-driven decisions in a fast-paced environment. Able to recognize trade-off decisions and can determine priorities and goals.
  • Strong written and business presentation skills is required.
  • Passion for innovation and a commitment to developing therapies that make a meaningful difference in patients' lives.
  • Demonstrated strong leadership presence.
  • Has demonstrated adaptability and flexibility.
  • Anticipates needs, assesses and manages business and organizational risks.
Responsibilities
  • Lead clinical science aspects of the clinical development strategy and clinical documentation.
  • Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as primary point-of-contact for questions/enquires regarding the CDP at a program level, oversee the conduct of medical/safety data reviews and study reporting.
  • Potential assignment to complex and high-priority strategic studies for Revolution Medicines’ molecules, with expectation to perform responsibilities with independence and clear self-directed leadership.
  • Cross-functionally align efforts seamlessly with scientific, regulatory, and commercial objects while executing upon the clinical development plan.
  • Lead, mentor, and contribute to a high-performing cross-functional team of clinical development professionals, fostering a culture of collaboration, innovation, and excellence.
  • Oversee all aspects of clinical trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
  • Establish and maintain strong relationships with clinical investigators, regulatory agencies, and key stakeholders.
  • Gather, analyze and interpret clinical data, providing strategic insights to inform critical decisions and guide program development.
  • Manage clinical development timelines effectively, ensuring efficient resource allocation and achievement of milestones.
  • Stay abreast of the latest scientific advancements and regulatory trends in the field of clinical development.
  • Potential to manage multiple direct reports.
Desired Qualifications
  • Has made significant contributions to clinical development plan conception, conduct and delivery, including successful alignment with scientific governance.
  • Experience in ongoing enhancements/development of core and sub-team processes, structures, systems, tools and other resources in the pharmaceutical/biotech industry.
  • Has led clinical development contributions to major regulatory submissions (e.g. (s)NDA, (s)BLA, PIP/PSP, label negotiation, Breakthrough Therapy Designation, Accelerated Review) is a major plus.
  • Proven ability to present the clinical development aspects of a program(s) to key major reference health authorities (FDA, EMA, others.) by teleconference or in-person.
  • Has led Health Authority interaction(s).
  • Proven ability to set out the clinical development strategy for CTA/EC submissions and responses to health authority questions.
  • Has demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. - resulting in demonstrable outcomes that have further enhanced strategic goals.
  • Influential and inspiring leader, with proven ability to bring teams and individuals along with them.
  • Has demonstrated courage and conviction in past positions and responsibilities. Demonstrated skills in conflict resolution.

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Daraxonrasib doubled survival in Phase 3 metastatic pancreatic cancer.
  • April 2026 financing added about $2.2 billion for development and commercialization.
  • Zoldonrasib showed 52% response rates in KRAS G12D NSCLC at AACR 2026.

What critics are saying

  • Daraxonrasib remains unapproved, so FDA timing can reset investor expectations.
  • Toxicities like rash and bleeding can force dose reductions and limit adoption.
  • Heavy spending and no product revenue keep dilution risk high through 2027.

What makes Revolution Medicines unique

  • Daraxonrasib targets active RAS, broadening coverage beyond single-mutation inhibitors.
  • Revolution Medicines built a proprietary RAS(ON) platform with multiple mutation-specific candidates.
  • Martin Burke's synthesis technology underpins the company's natural-product-inspired discovery approach.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Revolution Medicines who can refer or advise you

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
Journey to Wellness, Inc.
May 11th, 2026
Ben Sasse's pancreatic cancer response is giving new hope to patients watching experimental treatments closely.

Ben Sasse's pancreatic cancer response is giving new hope to patients watching experimental treatments closely. When someone with stage 4 pancreatic cancer says their tumors shrank by more than 70%, people pay attention. That's exactly what happened when former U.S. Senator Ben Sasse shared details about his response to an experimental drug called daraxonrasib. According to recent reports, Sasse entered a clinical trial after being diagnosed with metastatic pancreatic cancer that had already spread to other organs, including his liver and lungs. Doctors initially gave him only months to live. Now, after several months on the drug, he says his tumor burden has dropped dramatically. That doesn't mean pancreatic cancer suddenly has a cure. Not even close. But stories like this matter because they show something many patients and families already believe deep down. Cancer research is moving fast. Faster than most people realize. And for people facing diagnoses with limited standard treatment options, experimental therapies often become more than a headline. They become a source of hope. What is daraxonrasib? Daraxonrasib is an experimental targeted therapy being developed by Revolution Medicines. The drug is designed to target KRAS mutations, genetic alterations that play a major role in many cancers, especially pancreatic cancer. KRAS mutations are notoriously difficult to treat. For years, researchers referred to them as "undruggable." That phrase has started disappearing lately. Daraxonrasib works by interfering with mutated KRAS proteins that help cancer cells grow and spread uncontrollably. Early clinical trial data suggest the drug may significantly extend survival in some pancreatic cancer patients who have already gone through chemotherapy. Some reports from recent Phase 3 trial data showed median survival reaching 13.2 months compared to 6.7 months with chemotherapy alone. That may not sound dramatic to someone outside the cancer world. But pancreatic cancer is one of the deadliest cancers known. Even modest gains matter. Doubling survival time gets attention in oncology circles. Why pancreatic cancer is so difficult. Pancreatic cancer often grows quietly. Symptoms tend to appear late. By the time many patients are diagnosed, the disease has already spread beyond the pancreas. That's one reason survival rates remain so low compared to many other cancers. Researchers continue exploring new approaches, including: * Targeted therapies * Immunotherapy * Personalized cancer vaccines * Metabolic therapies * Combination treatment strategies * KRAS inhibitors like daraxonrasib Recently, experimental pancreatic cancer vaccines targeting KRAS mutations have also shown encouraging early results in some patients. You can feel the momentum building. Not just in one lab or one company. Across multiple areas of research. The part many headlines leave out. Sasse has also been very open about the side effects. In interviews, he described severe skin reactions, bleeding, fatigue, and painful complications from the drug. He even referred to it as a "nasty drug." That's important context. Experimental therapies can produce remarkable responses in some patients. They can also come with serious risks, unknowns, and difficult tradeoffs. Clinical trials exist partly because researchers are still learning who responds best, how long responses last, and what side effects patients may face. Not hype. Not despair either. Just honest curiosity about where cancer treatment may be heading. Why patients are paying attention. For many families dealing with pancreatic cancer, the standard roadmap can feel painfully short. So when patients hear about therapies that target specific mutations, personalized vaccines, or unexpected tumor regression, they start asking questions. They begin researching clinical trials. They look into precision medicine. They wonder whether their tumor has a KRAS mutation. They ask about genomic testing. Honestly, that shift may be one of the biggest developments in modern cancer care. Patients are becoming more informed. More engaged. More willing to explore emerging options alongside conventional treatment. And physicians are increasingly using genetic profiling to guide treatment decisions instead of relying only on cancer location or stage. A reminder worth holding onto. No single story proves a treatment works for everyone. But individual cases still matter. They remind people that research is ongoing. That outcomes are not always predictable. That medicine keeps evolving. Five years ago, many people had never heard of KRAS-targeted therapies. Now some researchers believe this category of drugs could open an entirely new chapter in pancreatic cancer treatment. For patients facing difficult diagnoses, even the possibility of another option matters. And sometimes, that's enough to keep people searching, asking questions, and refusing to give up.

CNBC
Apr 13th, 2026
Revolution Medicines' pancreatic cancer drug doubles survival to 13.2 months in late-stage trial

Revolution Medicines announced that its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial, nearly doubling survival time and reducing death risk by 60% compared to chemotherapy. Patients taking the daily pill typically survived 13.2 months versus 6.7 months with chemotherapy. The drug targets RAS mutations found in approximately 90% of pancreatic cancer cases. CEO Mark Goldsmith called the results "unprecedented", noting no drug has previously shown an overall survival benefit exceeding one year in Phase 3 pancreatic cancer trials. Revolution Medicines plans to seek FDA approval using a Commissioner's National Priority Voucher for expedited review. The approval would apply to second-line treatment for patients whose cancer progressed on other therapies. A separate Phase 3 trial for newly diagnosed patients is ongoing.

GAB
Apr 11th, 2026
Sasse spotlight on potential pancreatic cancer cure.

Sasse spotlight on potential pancreatic cancer cure. health April 11, 2026 health pancreatic cancer drug development RAS mutations Revolution Medicines' experimental drug daraxonrasib is showing promise as a potential breakthrough treatment for pancreatic cancer, garnering attention and driving up the company's stock. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, a drug that targets RAS mutations, which are present in about 90% of pancreatic cancer cases. The company anticipates releasing results from a Phase 3 trial soon, and it may become the first targeted treatment for this aggressive cancer. This development has significantly boosted RevMed's stock, increasing by nearly 185% over the past year, also making the company a prime acquisition target, according to reports. The drug gained recent attention when former Senator Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer, disclosed he is taking daraxonrasib. Sasse reported to The New York Times that his tumors have shrunk by 76% since starting the treatment. He did, however, note the drug's harsh side effects, including a rash that caused significant skin peeling. Despite these side effects, initial results are encouraging the medical community and patients. Why it matters. Pancreatic cancer is one of the deadliest forms of cancer, with only about 13% of patients surviving five years after diagnosis. This survival rate has remained relatively stagnant despite advancements in treating other cancers, making the unmet need for new therapies critically important. RBC Capital Markets analyst Leonid Timashev described RevMed's drug as potentially the biggest breakthrough in pancreatic cancer ever, highlighting the significance of a targeted treatment. Daraxonrasib aims to address the core mechanisms driving tumor growth in most pancreatic cancer cases, offering hope for improved outcomes. The broad targeting action of daraxonrasib on RAS mutations, while beneficial in attacking the cancer, also presents challenges. RAS proteins are widespread throughout the body, particularly in the skin, and the drug doesn't differentiate between mutated and normal RAS proteins. This leads to side effects such as rashes, as experienced by Senator Sasse. RevMed acknowledges these side effects but states that most rash cases have been low grade, and no patients have discontinued treatment due to them. The company describes reports of bleeding rashes as uncommon. What comes next. RevMed is proceeding with caution in its drug development, acknowledging the potential risks associated with daraxonrasib's broad RAS-targeting mechanism. CEO Mark Goldsmith noted the company started with a very low dose and gradually increased it, carefully monitoring patient tolerance. The company's scientists predicted that at 80 milligrams, tumors would start to shrink, a milestone they anxiously anticipated. The upcoming release of Phase 3 trial results will be crucial in determining the long-term efficacy and safety profile of daraxonrasib. Positive outcomes could lead to regulatory approval and make the drug available to a broader patient population. Continued monitoring for adverse effects and refinement of dosing strategies will also be essential to optimize treatment outcomes and improve patient quality of life. The drug's potential impact on the pharmaceutical landscape as a targeted therapy is significant. Faq. What is daraxonrasib and how does it work? What are the potential side effects of daraxonrasib? What stage of development is daraxonrasib in?

GAB
Apr 10th, 2026
Sasse spotlights potential pancreatic cancer breakthrough.

Sasse spotlights potential pancreatic cancer breakthrough. health April 10, 2026 health pancreatic cancer daraxonrasib Revolution Medicines Former Senator Ben Sasse's experience with Revolution Medicines' daraxonrasib has brought attention to a possible breakthrough in pancreatic cancer treatment, a disease with historically poor survival rates. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, an experimental drug that may become the first targeted treatment for pancreatic cancer. The company anticipates releasing results from a Phase 3 trial soon. Former Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer, is currently taking daraxonrasib. Sasse reported that his tumors have shrunk by 76% since starting the treatment, although he also noted significant side effects, including a severe rash. Sasse's public disclosure of his treatment has drawn significant attention to RevMed and its drug. The potential of daraxonrasib has already boosted RevMed's stock by nearly 185% over the past year, making the company an attractive acquisition target. The drug broadly targets RAS mutations, found in nearly 90% of pancreatic cancer cases. These mutations drive tumor growth, making them a key target for cancer therapy. While Sasse's experience is anecdotal, it has fueled optimism surrounding the drug's potential efficacy. Why it matters. Pancreatic cancer is one of the deadliest major cancers, with only 13% of patients surviving five years after diagnosis. This grim statistic has remained largely unchanged despite advancements in treating other cancers. Currently, there is no targeted treatment specifically for pancreatic cancer. Daraxonrasib represents a significant potential advancement because it directly targets the RAS mutations that are central to the disease's progression. RBC Capital Markets analyst Leonid Timashev described the drug as potentially the biggest breakthrough in pancreatic cancer ever. The drug's mechanism of action, while promising, also contributes to its side effects. RAS proteins are present throughout the body, and daraxonrasib cannot differentiate between mutated and normal RAS proteins. This broad activity leads to side effects like the rash experienced by Sasse. Despite these side effects, RevMed reports that most rash cases have been low grade, with no patients discontinuing treatment as a direct result. However, severe cases, including those with bleeding, have been reported anecdotally by clinical trial investigators. What comes next. RevMed is nearing the release of its Phase 3 trial results, which will be crucial in determining the drug's efficacy and safety profile. The company's initial cautious approach to dosing reflects concerns about tolerability, as daraxonrasib's broad activity against RAS proteins could lead to severe side effects. CEO Mark Goldsmith explained the painstaking process of gradually escalating the dose while closely monitoring patient response. The company's scientists had predicted that tumor shrinkage would begin at 80 milligrams. If the Phase 3 trial results are positive, daraxonrasib could become the first targeted treatment for pancreatic cancer, potentially transforming the prognosis for patients. The drug's success could also make RevMed a prime acquisition target for larger pharmaceutical companies. However, longer-term data will be required to understand the extent of rash severity and other side effects, and to ascertain whether daraxonrasib has lasting impact on survival rates. Further studies and patient testimonials will be essential to fully measure the efficacy and tolerability of daraxonrasib. Related topics on gab.ae: ai Faq. What is daraxonrasib? What are the side effects of daraxonrasib? What impact has the drug had on the company stock?

Yahoo Finance
Mar 28th, 2026
Revolution Medicines stock drops 8.8% post-earnings as Q4 loss of $1.86 per share misses estimates

Revolution Medicines shares have declined 8.8% in the month following its latest earnings report, underperforming the S&P 500. The biotech company reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company currently has no approved products or revenue. Research and development expenses rose 57% year over year to $294.9 million, driven by higher clinical study and manufacturing costs. General and administrative expenses increased more than 136% to $66.7 million. For 2026, Revolution Medicines expects operating expenses between $1.6 billion and $1.7 billion. Since the earnings release, analyst estimates have trended downward, with the consensus estimate shifting 7.21% lower. The stock maintains a Zacks Rank of Hold.

INACTIVE